Imunon, Inc. Common Stock
IMNNImmunoGen, Inc. (IMNN) is a biotechnology company focused on the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. The company leverages its proprietary ADC technology to create therapies designed to deliver potent cancer-killing agents directly to tumor cells, aiming to improve efficacy and reduce side effects associated with traditional chemotherapy.
Company News
IMUNON, Inc. (Nasdaq: IMNN) announced a conference call scheduled for March 31, 2026 at 11:00 a.m. EDT to discuss 2025 financial results and provide updates on its Phase 3 clinical trial (OVATION 3) for IMNN-001, a DNA-based IL-12 immunotherapy for advanced ovarian cancer treatment.
IMUNON announced progress in its Phase 3 OVATION 3 clinical trial for IMNN-001, a DNA-mediated immunotherapy targeting advanced ovarian cancer. The company has enrolled its first patient, implemented cost conservation measures, and introduced a 15% stock dividend to shareholders.
IMUNON, a clinical-stage biotechnology company, announced a $3.25 million private placement and the potential for an additional $6.5 million from the exercise of short-term warrants. The company plans to use the proceeds for working capital and general corporate purposes.
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform
